openPR Logo
Press release

Global Biosimilars Market projected to witness a CAGR of 40.14% and reach a total market value of US$19.151 billion in 2023

01-08-2019 03:02 PM CET | Health & Medicine

Press release from: Knowledge Sourcing Intelligence LLP

Global Biosimilars Market projected to witness a CAGR of 40.14%

The report published by Knowledge Sourcing Intelligence titled “Global Biosimilar Market- Forecast From 2018 to 2023” studies the various factors affecting the demand for biosimilars worldwide. The report has been segmented by Type (Monoclonal Antibodies, Recombinant Proteins, Hormones and others), Disease (infectious Disease, Oncology and Immunology, Respiratory, Genetic Disorders and others).

In addition, the Global Biosimilars market has been estimated based on the geography, covering five regions namely North America, South America, Europe, Middle East and Africa and the Asia Pacific, and some of the major economies in each of these regions. The demand for biosimilars would primarily be driven by cost-effectiveness as compared to reference biologics, coupled with increasing investment by the companies towards the development of efficient biosimilars. Moreover, patent expiration of the many blockbuster biologic drugs will pose an interesting opportunity for existing and new market players around the world. However, structural complexity of the biosimilar drugs and multi-layered manufacturing might restrain the growth of the market during the given time frame.

Request sample: www.knowledge-sourcing.com/requestsample&sample_id=1640

Monoclonal antibodies is projected to hold a significant market share in the global biosimilar market in 2018

It is estimated that monoclonal antibodies will hold a significant share in the global biosimilars market owing to the rising research and development of the therapeutic antibodies coupled with the advantages such as homogeneity, specificity, and large-scale production; and fewer side effects related to substitute drugs. Increasing demand for personalized medicine will also contribute to the growth of the segment during the given forecast period.

Europe region is estimated to hold the dominant share in the global biosimilars market throughout the forecast period

Geographically, Europe holds the largest market share due to the presence of well-known biopharmaceutical players such as Stada, Sandoz, AstraZeneca, Merck etc. Also well-defined regulatory framework for the approval of biosimilars and rising number of product approvals coupled with well-developed healthcare infrastructure have further provided a boost to the European biosimilar market. North America will also show robust growth during the forecast period owing to the increasing focus on the product development coupled with the rising efforts from the manufacturers to tap the growth opportunities in the region.

This report also includes a study of strategies and product portfolios of some of the leading companies in the global biosimilars market. It consists of company profiles of the leading companies such as Samsung Bioepis, Sandoz International GmbH (A Novartis Company) and Boehringer Ingelheim International GmbH among others.

Request customization or place your order: www.knowledge-sourcing.com/global-biosimilar-market

About Us:
Knowledge Sourcing Intelligence (KSI) is a market research and consulting organization based out of India. KSI publishes research studies spanning across ten industry verticals. KSI has a team of experienced and young professionals with a singular focus on delivering high-quality research services to enterprises, non-government organizations, government agencies, and research institutes and organizations. We publish hundreds of reports per year centring on niche and latest technologies. We engage with key decision makers and stakeholders across the value chain to provide clients with a detailed analysis and bird’s-eye view of the market with whole market dynamics, statistical forecasts, competitive analysis, key trends, market drivers and challenges and strategic recommendations for making informed decisions. Our success lies in the effort of our analysts who strive to meet client expectations by delivering quality work within the stipulated deadlines.

Contact Us:
Knowledge Sourcing Intelligence LLP
2nd Floor, D-77, Sector 63
Noida, U.P. - 201301
India
E: sales@knowledge-sourcing.com | P: +1-866-714-4587

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilars Market projected to witness a CAGR of 40.14% and reach a total market value of US$19.151 billion in 2023 here

News-ID: 1477629 • Views: 119

More Releases from Knowledge Sourcing Intelligence LLP

Sports Technology Market to Reach USD 33.63 Billion by 2024
​​​​​The recent study on the Sports Technology Market covers an in-depth analysis of the market by type, sport, and geography. The report also covers the country-level analysis within the regions as well. Additionally, the report covers the key trends in the market along with drivers and restraint during the forecast period. According to the report titled “Sports Technology Market – Forecast from 2019 to 2024,” the market is estimated to
Discrete semiconductor market to witness a CAGR of 2.94% between 2018 and 2024
The recent study on the global discrete semiconductor market covers an in-depth analysis of the market on the basis of type, industry vertical, and geography. The report also covers the country-level analysis within the regions as well. Additionally, the report covers the key trends in the market along with drivers and restraint during the forecast period 2019-2024. According to the report titled “Global Discrete Semiconductor Market– Forecast from 2019 to
Revenue Cycle Management Market Segmented by Product, Application, and Geography …
The recent study on the revenue cycle management market covers an in-depth analysis of the market on the basis of product, application, and geography. The report also covers the country level analysis within the regions as well. In addition, the report covers the key trends in the market along with drivers and restraints during the forecast period 2019-2024. According to the report titled “Revenue Cycle Management Market - Forecasts From
Automotive Catalyst Market Segmented by Type, Vehicle Type, and Geography (2019 …
The recent study on the automotive catalyst market covers in-depth analysis of the market on the basis of type, vehicle type, and geography. The report also covers the country level analysis within the regions as well. Additionally, the report covers the key trends in the market along with drivers and restraint during the forecast period 2019-2024. The report has segmented the automotive catalyst market by type (oxidation catalyst, three-way catalyst,

All 5 Releases


More Releases for Biosimilar

Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.